Correlation Between Coronary and Carotid Atherosclerotic Disease (CAD) and Links With Clinical Outcomes

Patients with clinical indication for coronary angiography

Inclusion Criteria:

• Male and female patients over the age of 18 years.
• Patients scheduled for clinically indicated coronary angiography and possible ad hoc percutaneous coronary intervention (PCI) will be evaluated before their scheduled procedure.
• Written informed consent (approved by the Institutional Review Board [IRB]/Independent Ethics Committee [IEC]) obtained prior to any study specific procedures.
• Patients considered to be stable at enrollment (at the discretion of the investigator) are eligible provided they meet all other entry criteria.
• Angiogram meeting qualifying criteria

Exclusion Criteria:

• Women of childbearing potential (women who are not surgically sterile or postmenopausal defined as amenorrhea for >12 months) who refuse to undergo a urine or serum pregnancy test immediately prior to baseline and repeat imaging evaluations The urine or serum pregnancy test must be negative prior to imaging evaluations.
• Previous coronary artery bypass graft (CABG) surgery or probable need for CABG in the next 24 months.
• Patients who have symptomatic congestive heart failure (CHF) (New York Heart Association [NYHA] Class III or IV) at baseline.
• Patients with clinically significant valvular heart disease likely to require surgical repair or replacement during the treatment period of the study
• Any clinically significant medical condition or presence of any laboratory abnormality that is considered by the investigator to be clinically important and could interfere with the conduct of the study.
• The presence of severe liver disease as defined by the presence of cirrhosis, chronic active hepatitis, or chronic jaundice with hyperbilirubinemia,
• Patients with eGFR < 45 ml/min prior to baseline imaging procedures, or with nephrotic syndrome
• Patients with a life expectancy less than 2 years.
• History of malignancy (except for curatively treated basal cell or squamous cell carcinoma of the skin) during the 3 years prior to the screening.
• Unable or unwilling to comply with protocol requirements, or deemed by the investigator to be unfit for the study.